# name
New therapies targeting the PD1/PDL-1 pathway for lung cancer

# metadata.dc.description[].value
Treballs Finals de Grau de Farmàcia, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 2020. Tutor/a: Noé Mata, Verónica

# metadata.dc.description.abstract[].value
Lung cancer is giving promising results in immunotherapy treatments, even though it is one of the cancers with worse prognosis. Silencing of the PD1 / PDL-1 pathway is one of the most widely used strategies for this type of cancer. This pathway is usually found to be overexpressed in lung cancer; it should be noted that it helps tumor cells to evade the anti-tumor response of the immune system. PPRHs are DNA molecules used 
for gene silencing. They were recently discovered and have been previously tested in other types of cancer to modulate the PD1 / PDL-1 pathway. During the present research project, the main objective was to validate the PPRHs strategy to inhibit the PD1/PDL-1 pathway  as  a  possible  treatment  of  pulmonary  adenocarcinoma.  THP-1  cells  were 
differentiated to macrophages with PMA. Different PPRHs against PD1 and PDL-1 were designed  and  tested  in  THP-1  and  A549  cell  lines,  first  separately,  testing  for  cross toxicity and then in co-culture. Cell viability was assessed by MTT assays. Differentiation of  THP-1  to  macrophages  showed  no  significant  differences  at  three  different 
concentrations of PMA. Cross-toxicity assays showed a decrease in cell viability when transfecting A549 cells with PPRHs against PD1, whereas this effect was not observed in THP-1 transfected with PPRHS against PDL-1. Co-culture experiment showed that the combination  of  PPRHs  against  PD1  and  PDL-1  produced  an  enhancement  of  the 
antitumor effect, compared to their individual effects separately. Our results support the usage of PPRHs for the silencing PD1/PDL-1 pathway in lung cancer.

# metadata.dc.source[].value
Treballs Finals de Grau (TFG) - Farmàcia

# metadata.dc.title[].value
New therapies targeting the PD1/PDL-1 pathway for lung cancer